1
|
Jeon OH, Mehdipour M, Gil TH, Kang M, Aguirre NW, Robinson ZR, Kato C, Etienne J, Lee HG, Alimirah F, Walavalkar V, Desprez PY, Conboy MJ, Campisi J, Conboy IM. Systemic induction of senescence in young mice after single heterochronic blood exchange. Nat Metab 2022; 4:995-1006. [PMID: 35902645 PMCID: PMC9945470 DOI: 10.1038/s42255-022-00609-6] [Citation(s) in RCA: 44] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 06/15/2022] [Indexed: 01/28/2023]
Abstract
ABSTACT Ageing is the largest risk factor for many chronic diseases. Studies of heterochronic parabiosis, substantiated by blood exchange and old plasma dilution, show that old-age-related factors are systemically propagated and have pro-geronic effects in young mice. However, the underlying mechanisms how bloodborne factors promote ageing remain largely unknown. Here, using heterochronic blood exchange in male mice, we show that aged mouse blood induces cell and tissue senescence in young animals after one single exchange. This induction of senescence is abrogated if old animals are treated with senolytic drugs before blood exchange, therefore attenuating the pro-geronic influence of old blood on young mice. Hence, cellular senescence is neither simply a response to stress and damage that increases with age, nor a chronological cell-intrinsic phenomenon. Instead, senescence quickly and robustly spreads to young mice from old blood. Clearing senescence cells that accumulate with age rejuvenates old circulating blood and improves the health of multiple tissues.
Collapse
Affiliation(s)
- Ok Hee Jeon
- Buck Institute for Research on Aging, Novato, CA, USA.
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea.
| | - Melod Mehdipour
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA
| | - Tae-Hwan Gil
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea
| | - Minha Kang
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea
| | | | - Zachery R Robinson
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA
| | - Cameron Kato
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA
| | - Jessy Etienne
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA
| | - Hyo Gyeong Lee
- Department of Biomedical Sciences, Korea University College of Medicine, Seoul, Republic of Korea
| | | | | | | | - Michael J Conboy
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA
| | - Judith Campisi
- Buck Institute for Research on Aging, Novato, CA, USA.
- Lawrence Berkeley National Laboratory, Berkeley, CA, USA.
| | - Irina M Conboy
- Department of Bioengineering and QB3 Institute, University of California, Berkeley, CA, USA.
| |
Collapse
|
2
|
Castellano JM. Blood-Based Therapies to Combat Aging. Gerontology 2018; 65:84-89. [PMID: 30196300 DOI: 10.1159/000492573] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 07/31/2018] [Indexed: 12/23/2022] Open
Abstract
Dysfunction associated with the aging process positions aging as a leading culprit for development of devastating diseases and mounting health-care costs. Many age-associated conditions for which aging increases risk are neurological disorders with no effective treatments, including Alzhei-mer's disease. As the proportion of aged individuals continues to rise in the coming decades, aging-related costs are expected to increase dramatically. Diverse approaches have emerged to meet the clinical need to treat aging and its associated conditions, including those aimed at increasing longevity, slowing the aging process itself, and improving healthspan. An emerging approach takes advantage of molecules circulating in the blood to limit or reverse aspects of aging in various organs throughout the body. Efforts are underway to translate these findings into novel therapeutics that harness the activity of youth-associated molecules present within blood. Here, we discuss the current state of blood-based approaches in this arena. Despite the apparent ease with which blood products might conceivably be applied as treatment paradigms, we propose that challenges nonetheless exist, which may be overcome with mechanistic studies that identify common pathways for targeted therapeutics.
Collapse
|